var data={"title":"Risperidone: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Risperidone: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6917?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=risperidone-drug-information\" class=\"drug drug_general\">see &quot;Risperidone: Drug information&quot;</a> and <a href=\"topic.htm?path=risperidone-patient-drug-information\" class=\"drug drug_patient\">see &quot;Risperidone: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50629650\" class=\"block spa drugH1Div\"><span class=\"drugH1\">Special Alerts</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Atypical Antipsychotics Safety Review</span>\n      <span class=\"collapsible-date\">September 2017</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:0em;\">Health Canada has reviewed the potential risk of sleep walking and sleep-related eating disorder with the use of atypical antipsychotics and concluded there is a link between these adverse reactions and the use of these medications. Health Canada has recommended to update the product safety information for all atypical antipsychotics to include these adverse reactions.</p>\n        <p style=\"text-indent:0em;\">Further information may be found at https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/safety-reviews/atypical-antipsychotics-assessing-potential-risk-sleep-walking-sleep-related-eating-disorder.html.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5709402\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Increased mortality in elderly patients with dementia-related psychosis:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Analyses of 17 placebo-controlled trials (modal duration of 10 weeks), largely in patients taking atypical antipsychotic drugs, revealed a risk of death in the drug-treated patients of between 1.6 and 1.7 times the risk of death in placebo-treated patients. Over the course of a typical 10-week controlled trial, the rate of death in drug-treated patients was approximately 4.5% compared with a rate of approximately 2.6% in the placebo group. Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (eg, heart failure, sudden death) or infectious (eg, pneumonia) in nature. Observational studies suggest that similar to atypical antipsychotic drugs, treatment with conventional antipsychotic drugs may increase mortality. The extent to which the findings of increased mortality in observational studies may be attributed to the antipsychotic drug as opposed to some characteristic(s) of the patients is not clear. Risperidone is not approved for the treatment of patients with dementia-related psychosis.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218658\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>RisperDAL;</li>\n      <li>RisperDAL Consta;</li>\n      <li>RisperDAL M-TAB;</li>\n      <li>RisperiDONE M-TAB</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218659\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Risperdal;</li>\n      <li>Risperdal Consta;</li>\n      <li>Risperdal M-Tab</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1055300\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antipsychotic Agent, Benzisoxazole</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Second Generation (Atypical) Antipsychotic </span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1055292\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=risperidone-drug-information\" class=\"drug drug_general\">see &quot;Risperidone: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Autism, associated irritability, including aggression, temper, tantrums, self-injurious behavior, and quickly changing moods:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &ge;5 years and Adolescents: <b>Note:</b> Individualize dose according to patient response and tolerability:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">15 to 20 kg: Oral: Initial: 0.25 mg/day; after &ge;4 days, may increase dose to 0.5 mg/day; maintain this dose for &ge;14 days. In patients not achieving sufficient clinical response, may increase dose in increments of 0.25 mg/day at &ge;2-week intervals. Doses ranging from 0.5 to 3 mg/day have been evaluated; however, therapeutic effect reached plateau at 1 mg/day in clinical trials. Following clinical response, consider gradually decreasing dose to lowest effective dose. May be administered once daily or in divided doses twice daily.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&ge;20 kg: Oral: Initial: 0.5 mg/day; after &ge;4 days, may increase dose to 1 mg/day; maintain this dose for &ge;14 days. In patients not achieving sufficient clinical response, may increase dose in increments of 0.5 mg/day at &ge;2-week intervals. Doses ranging from 0.5 to 3 mg/day have been evaluated; however, therapeutic effect reached plateau at 2.5 mg/day (3 mg/day in pediatric patients &gt;45 kg) in clinical trials. Following clinical response, consider gradually decreasing to lowest effective dose. May be administered once daily or in divided doses twice daily.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Bipolar mania:</b> Children and Adolescents 10 to 17 years: Oral: Initial: 0.5 mg once daily; dose may be adjusted if needed, in increments of 0.5 to 1 mg/day at intervals &ge;24 hours, as tolerated, to a dose of 2.5 mg/day. Doses ranging from 0.5 to 6 mg/day have been evaluated; however, doses &gt;2.5 mg/day do not confer additional benefit and are associated with increased adverse events; doses &gt;6 mg/day have not been studied. <b>Note:</b> May administer <sup>1</sup>/<sub>2</sub> the daily dose twice daily in patients who experience persistent somnolence.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Delirium:</b> Limited data available:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &lt;5 years: Oral: Initial: 0.1 to 0.2 mg once daily at bedtime; dosing based on retrospective review of 10 pediatric patients (ages: 4 months to 16 years) which included three patients &lt;5 years of age (Schieveld 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &ge;5 years and Adolescents: Oral: Initial: 0.2 to 0.5 mg once daily at bedtime; may titrate to lowest effective dose every 1 to 2 days; usual range: 0.2 to 2.5 mg/day in divided doses 2 to 4 times daily; maximum daily dose dependent upon patient weight: &lt;20 kg: 1 mg/day; 20 to 45 kg: 2.5 mg/day, &gt;45 kg: 3 mg/day (Karnik 2007; Schieveld 2007; Silver 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Disruptive behavior disorders (eg, conduct disorder, oppositional defiant disorder):</b> Limited data available: Children &ge;4 years and Adolescents: Oral: Initial: 0.01 mg/kg/dose once daily for 2 days, then 0.02 mg/kg/dose once daily, may further increase on weekly basis as tolerated to 0.06 mg/kg/dose once daily; usual maximum daily dose: 2 mg/<b>day</b>; improvement in target symptoms typically within 1 to 4 weeks (Aman 2002; Findling 2004; Kutcher 2004; Pandina 2006). <b>Note:</b> May administer <sup>1</sup>/<sub>2</sub> the daily dose twice daily if breakthrough symptoms occur in the afternoon or evening.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Pervasive developmental disorders (PDD) (eg, disruptive behavior, aggression, irritability):</b> Limited data available: Children &ge;5 years and Adolescents: Oral: Initial: 0.01 mg/kg/dose once daily for 2 days, then 0.02 mg/kg/dose once daily; may further increase on weekly basis by &le;0.02 mg/kg/day increments as tolerated to 0.06 mg/kg/dose once daily; reported mean dose: 0.05 mg/kg/day (1.48 mg/day); other trials have reported similar optimal doses: 0.75 to 1.8 mg/day; improvement in target symptoms typically within 2 to 4 weeks (Fisman 1996; McDougle 1997; Shea 2004). <b>Note:</b> May administer <sup>1</sup>/<sub>2</sub> the daily dose twice daily if breakthrough symptoms occur in the afternoon or evening.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Schizophrenia:</b> Adolescents 13 to 17 years: Oral: Initial: 0.5 mg once daily; dose may be adjusted if needed, in increments of 0.5 to 1 mg/day at intervals &ge;24 hours, as tolerated, to a dose of 3 mg/day. Doses ranging from 1 to 6 mg/day have been evaluated; however, doses &gt;3 mg/day do not confer additional benefit and are associated with increased adverse events. <b>Note:</b> May administer <sup>1</sup>/<sub>2</sub> the daily dose twice daily in patients who experience persistent somnolence.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Tourette syndrome, tics:</b> Limited data available: Children &ge;7 years and Adolescents: Oral: Initial: 0.25 to 0.5 mg once daily at night; may gradually titrate every 4 to 5 days in 0.25 to 0.5 mg increments to usual reported therapeutic range: 0.25 to 6 mg/day divided in twice daily doses (Dion 2002; Roessner 2011; Scahill 2003; Singer 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: <b>Note:</b> When reinitiating treatment after discontinuation, the initial titration schedule should be followed.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Bipolar mania:</b> Oral: Initial: 2 to 3 mg/dose once daily; adjust dose as needed, by 1 mg/day increments at intervals &ge;24 hours; dosing range: 1 to 6 mg/day; no dosing recommendation available for treatment &gt;3 weeks duration</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Bipolar I, maintenance:</b> IM (RisperDAL Consta): 25 mg every 2 weeks; if unresponsive, some may benefit from larger doses (37.5 to 50 mg); maximum dose: 50 mg every 2 weeks. Dosage adjustments should not be made more frequently than every 4 weeks. A lower initial dose of 12.5 mg may be appropriate in some patients (eg, demonstrated poor tolerability to other psychotropic medications).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Note:</b> Oral risperidone (or other antipsychotic) should be administered with the initial injection of RisperDAL Consta and continued for 3 weeks (then discontinued) to maintain adequate therapeutic plasma concentrations prior to main release phase of risperidone from injection site. When switching from depot administration to a short-acting formulation, administer short-acting agent in place of the next regularly scheduled depot injection.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Schizophrenia:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral: Initial: 2 mg/day in 1 to 2 divided doses; may be increased by 1 to 2 mg/day at intervals &ge;24 hours to a recommended dosage range of 4 to 8 mg/day; may be given as a single daily dose once maintenance dose is achieved; daily dosages &gt;6 mg do not appear to confer any additional benefit and the incidence of extrapyramidal symptoms is higher than with lower doses. Further dose adjustments should be made in increments/decrements of 1 to 2 mg/day on a weekly basis. Dose range studied in clinical trials: 4 to 16 mg/day. Maintenance: Recommended dosage range: 2 to 8 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IM: (RisperDAL Consta): Initial: 25 mg every 2 weeks; if unresponsive, some may benefit from larger doses (37.5 to 50 mg); maximum dose: 50 mg every 2 weeks. Dosage adjustments should not be made more frequently than every 4 weeks. A lower initial dose of 12.5 mg may be appropriate in some patients (eg, demonstrated poor tolerability to psychotropic medications).</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <b>Note:</b> Oral risperidone (or other antipsychotic) should be administered with the initial injection of RisperDAL Consta and continued for 3 weeks (then discontinued) to maintain adequate therapeutic plasma concentrations prior to main release phase of risperidone from injection site. When switching from depot administration to a short-acting formulation, administer short-acting agent in place of the next regularly scheduled depot injection.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Discontinuation</b>\n      <b> of therapy:</b> Children, Adolescents, and Adults: American Academy of Child and Adolescent Psychiatry (AACAP), American Psychiatric Association (APA), Canadian Psychiatric Association (CPA), National Institute for Health and Care Excellence (NICE), and World Federation of Societies of Biological Psychiatry (WFSBP) guidelines recommend gradually tapering antipsychotics to avoid withdrawal symptoms and minimize the risk of relapse (AACAP [McClellan 2007]; APA [Lehman 2004]; Cerovecki 2013; CPA 2005; NICE 2013; WFSBP [Hasan 2012]); risk for withdrawal symptoms may be highest with highly anticholinergic or dopaminergic antipsychotics (Cerovecki 2013). When stopping antipsychotic therapy in patients with schizophrenia, the CPA guidelines recommend a gradual taper over 6 to 24 months and the APA guidelines recommend reducing the dose by 10% each month (APA [Lehman 2004]; CPA 2005). Continuing antiparkinsonism agents for a brief period after discontinuation may prevent withdrawal symptoms (Cerovecki 2013). When switching antipsychotics, three strategies have been suggested: Cross-titration (gradually discontinuing the first antipsychotic while gradually increasing the new antipsychotic), overlap and taper (maintaining the dose of the first antipsychotic while gradually increasing the new antipsychotic, then tapering the first antipsychotic), and abrupt change (abruptly discontinuing the first antipsychotic and either increasing the new antipsychotic gradually or starting it at a treatment dose). Evidence supporting ideal switch strategies and taper rates is limited and results are conflicting (Cerovecki 2013; Remington 2005).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Dosing adjustment in renal impairment:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children and Adolescents: There are no dosage adjustments provided in manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral: CrCl &lt;30 mL/minute: Initial: 0.5 mg twice daily; increase (as tolerated) in increments of &le;0.5 mg twice daily; increases to dosages &gt;1.5 mg twice daily should be made at intervals of &ge;1 week; slower titration may be required in some patients. Clearance of the active moiety (sum of parent drug and active metabolite) is decreased by 60% in patients with moderate to severe renal disease (CrCl &lt;60 mL/minute) compared to healthy subjects.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IM: Initiate with <b>oral</b> dosing (0.5 mg twice daily for 1 week, then 2 mg/day for 1 week); if tolerated, begin 25 mg <b>IM</b> every 2 weeks; continue oral dosing for 3 weeks after the first IM injection. An initial IM dose of 12.5 mg may also be considered.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children and Adolescents: There are no dosage adjustments provided in manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral: Child-Pugh Class C: Initial: 0.5 mg twice daily; increase (as tolerated) in increments of &le;0.5 mg twice daily; increases to dosages &gt;1.5 mg twice daily should be made at intervals of &ge;1 week; slower titration may be required in some patients. The mean free fraction of risperidone in plasma was increased by 35% in patients with hepatic impairment compared to healthy subjects.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IM: Initiate with <b>oral</b> dosing (0.5 mg twice daily for 1 week, then 2 mg/day for 1 week); if tolerated, begin 25 mg <b>IM</b> every 2 weeks; continue oral dosing for 3 weeks after the first IM injection. An initial IM dose of 12.5 mg may also be considered.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218631\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">RisperDAL: 1 mg/mL (30 mL) [contains benzoic acid]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 1 mg/mL (30 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension Reconstituted, Intramuscular: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">RisperDAL Consta: 12.5 mg (1 ea); 25 mg (1 ea); 37.5 mg (1 ea); 50 mg (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">RisperDAL: 0.25 mg, 0.5 mg, 1 mg [contains corn starch]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">RisperDAL: 2 mg [contains corn starch, fd&amp;c yellow #6 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">RisperDAL: 3 mg [contains corn starch, fd&amp;c yellow #10 (quinoline yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">RisperDAL: 4 mg [contains corn starch, fd&amp;c blue #2 aluminum lake, fd&amp;c yellow #10 (quinoline yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Disintegrating, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">RisperDAL M-TAB: 0.5 mg, 1 mg, 2 mg [DSC], 3 mg, 4 mg [contains aspartame, peppermint oil (mentha piperita oil)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">RisperiDONE M-TAB: 0.5 mg, 1 mg, 2 mg, 3 mg [DSC], 4 mg [DSC] [contains aspartame]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218617\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1055303\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Oral: May be administered without regard to meals.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Oral solution: May administer directly from the manufacturer provided calibrated pipette or may mix with water, coffee, orange juice, or low-fat milk; do not mix with cola or tea; <b>Note:</b> Manufacturer provided calibrated pipette is calibrated in milligrams and milliliters; minimum calibrated volume: 0.25 mL; maximum calibrated volume: 3 mL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Orally-disintegrating tablets: Do not remove tablet from blister pack until ready to administer; do not push tablet through foil (tablet may become damaged); peel back foil to expose tablet; use dry hands to remove tablet and place immediately on tongue; tablet will dissolve within seconds and may be swallowed with or without liquid; do not split or chew tablet</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">IM: After reconstitution, shake vial vigorously for a minimum of 10 seconds to properly mix; suspension should appear thick, milky, and uniform; use immediately (or within 6 hours of reconstitution); if suspension settles prior to use, shake vigorously to resuspend. Administer deep IM into either the deltoid muscle or the upper-outer quadrant of the gluteal area; avoid inadvertent injection into blood vessel; <b>do not administer IV;</b> alternate injection site between the two arms or buttocks; do not combine two different dosage strengths into one single administration; administer with needle provided (1-inch needle for deltoid administration or 2-inch needle for gluteal administration); do not substitute any components of the dose pack.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49133431\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 2]).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">NIOSH recommends single gloving for administration of intact tablets or capsules. NIOSH recommends double gloving, a protective gown, and (if there is a potential for vomit or spit up) eye/face protection for administration of an oral liquid/feeding tube administration. For IM preparation, double gloves, a protective gown, and ventilated engineering controls (a class II biological safety cabinet or a compounding aseptic containment isolator) are recommended. Double gloving and a protective gown are required during IM administration (NIOSH 2016). Assess risk to determine appropriate containment strategy (USP-NF 2017).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218653\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Injection: Risperdal Consta: Store at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F) and protect from light. May be stored at 25&deg;C (77&deg;F) for up to 7 days prior to administration; do not expose unrefrigerated product to temperatures above 77&deg;F (25&deg;C). Following reconstitution, administer immediately (do not store for future use).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Oral solution, tablet: Store at 15&deg;C to 25&deg;C (59&deg;F to 77&deg;F). Protect from light and moisture. Keep orally-disintegrating tablets sealed in foil pouch until ready to use. Do not freeze solution.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1055302\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Oral: Management of schizophrenia (FDA approved in ages &ge;13 years and adults); treatment of acute mania or mixed episodes associated with bipolar I disorder (FDA approved as monotherapy in ages &ge;10 years and adults; FDA approved in combination with lithium or valproate in adults); treatment of irritability (including aggression, temper tantrums, self-injurious behavior, and quickly changing moods) associated with autistic disorder in children and adolescents (FDA approved in ages 5-16 years); has also been used for treatment of Tourette syndrome (tics), disruptive behavior disorders, and delirium and irritability in the management of pervasive development disorders.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">IM: Management of schizophrenia (FDA approved in adults); maintenance treatment of bipolar I disorder as monotherapy or in combination with lithium or valproate (FDA approved in adults)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218713\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">RisperiDONE may be confused with reserpine, rOPINIRole</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">RisperDAL may be confused with lisinopril, reserpine, Restoril</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Geriatric Patients: High-Risk Medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Beers Criteria: Antipsychotics are identified in the Beers Criteria as potentially inappropriate medications to be avoided in patients 65 years and older with dementia due to an increased risk of mortality, cerebrovascular accidents (stroke), and a greater rate of cognitive decline with use; avoid antipsychotics for behavioral problems associated with dementia or delirium unless alternative nonpharmacologic therapies have failed and patient may harm self or others. Use <i>may be appropriate</i> in geriatric patients with schizophrenia, bipolar disorder, or for short-term use as an antiemetic during chemotherapy. In addition, antipsychotics should be used with caution in older adults due to their potential to cause or exacerbate syndrome of inappropriate antidiuretic hormone secretion (SIADH) or hyponatremia; monitor sodium closely with initiation or dosage adjustments in older adults (Beers Criteria [AGS 2015]).</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218711\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Bradycardia, bundle branch block, chest pain, ECG changes, facial edema, first degree atrioventricular block, hypertension, hypotension, orthostatic hypotension, palpitations, peripheral edema, prolonged Q-T interval on ECG, syncope, tachycardia (more common in adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Abnormal gait, agitation, akathisia, anxiety, ataxia, depression, disturbance in attention, disturbed sleep, dizziness, drooling (more common in children), drowsiness (more common in adults), dystonia, falling, fatigue (more common in children), headache, hypoesthesia, insomnia, lethargy, malaise, nervousness, orthostatic dizziness, pain, paresthesia, parkinsonian-like syndrome (more common in children), sedation (more common in children), seizure, tardive dyskinesia, vertigo</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Acne vulgaris, eczema, pruritus, skin sclerosis, skin rash, xeroderma</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Amenorrhea, decreased libido, galactorrhea, glycosuria, gynecomastia, hyperglycemia, hyperprolactinemia, increased gamma-glutamyl transferase, increased thirst (more common in children), oligomenorrhea, weight gain (more common in children), weight loss</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal pain (more common in children), anorexia, constipation, decreased appetite, diarrhea, dyspepsia, gastritis, gastroenteritis, increased appetite (more common in children), nausea, sialorrhea, toothache, vomiting (more common in children), xerostomia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Cystitis, ejaculatory disorder, erectile dysfunction, irregular menses, mastalgia, menstruation, sexual disorder, urinary incontinence (more common in children), urinary tract infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Anemia, neutropenia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Increased serum ALT, increased serum AST</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infection: Infection, influenza, localized infection, subcutaneous abscess, viral infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Induration at injection site, injection site reaction, local pain (buttock), pain at injection site, swelling at injection site</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Abnormal posture, akinesia, arthralgia, back pain, dyskinesia (more common in adults), hypokinesia, increased creatine phosphokinase, limb pain, musculoskeletal chest pain, myalgia, neck pain, tremor (more common in adults), weakness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Blurred vision, conjunctivitis, reduced visual acuity</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Otic: Otalgia, otic infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Bronchitis, cough (more common in children), dyspnea, epistaxis, flu-like symptoms, nasal congestion, nasopharyngitis (more common in children), pharyngitis, pharyngolaryngeal pain, pneumonia, respiratory tract infection, rhinitis, rhinorrhea (more common in children), sinus congestion, sinusitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever (more common in children)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Abnormal erythrocytes, abscess at injection site, acariasis, agranulocytosis, alopecia, anaphylaxis, angioedema, anorgasmia, apnea, aspiration, atrial fibrillation, atrial premature contractions, blepharospasm, blunted affect, breast hypertrophy, bronchopneumonia, cellulitis, cerebral ischemia, cerebrovascular accident, cerebrovascular disease, cheilitis, chills, cholestatic hepatitis, cholinergic syndrome, cold extremities, coma, confusion, crusting of eyelid, cutaneous nodule, cyst, decreased hematocrit, decreased hemoglobin, dehydration, delirium, depression of ST segment on ECG, dermal ulcer, dermatological disease, desquamation, diabetes mellitus, diabetic coma, diabetic ketoacidosis, disruption of body temperature regulation, diverticulitis, dry eye syndrome, dysgeusia, dysphagia, dysuria, edema, eosinophilia, erythema, esophageal motility disorder, esophagitis, eye discharge, eye infection, eyelid edema, fecal incontinence, fecaloma, feeling abnormal, flushing, glaucoma, granulocytopenia, hematemesis, hematoma, hematuria, hemorrhage, hepatic failure, hepatic injury, hyperkeratosis, hyperphosphatemia, hyperthermia, hypertonia, hypertriglyceridemia, hyperuricemia, hyperventilation, hypoglycemia, hypokalemia, hyponatremia, hypoproteinemia, hypothermia, impaired consciousness, increased serum cholesterol, increased serum transaminases, intestinal obstruction, intraoperative floppy iris syndrome, inversion T wave on ECG, jaundice, joint stiffness, joint swelling, lacrimation, leukocytosis, leukopenia, leukorrhea, lip edema, loss of balance, lower respiratory tract infection, lymphadenopathy, mania, mastitis, migraine, movement disorder, myocardial infarction, myocarditis, nasal mucosa swelling, neuroleptic malignant syndrome, nystagmus, oculogyric crisis, ocular hyperemia, onychomycosis, pancreatitis, Pelger-Huet anomaly, phlebitis, photophobia, pitting edema, pituitary neoplasm, pollakiuria, polydipsia, precocious puberty, priapism, pulmonary congestion, pulmonary embolism, rales, renal insufficiency, respiratory congestion, respiratory distress, retinal artery occlusion, retrograde ejaculation, rhabdomyolysis, rigors, sarcoidosis, seborrhea, seborrheic dermatitis of scalp, SIADH, skin discoloration, skin lesion, sleep apnea, speech disturbance, stomatitis, stridor, swelling of eye, synostosis, thrombocytopenia, thrombophlebitis, thrombotic thrombocytopenic purpura, tinnitus, tissue necrosis, tongue discoloration, tongue edema, tongue paralysis, tongue spasm, tonsillitis, torticollis, tracheobronchitis, transient ischemic attacks, unresponsive to stimuli, urinary retention, urticaria, vaginal discharge, ventricular premature contractions, ventricular tachycardia, voice disorder, water intoxication, wheezing, withdrawal syndrome, xerophthalmia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218638\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to risperidone, paliperidone, or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218621\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Altered cardiac conduction: May alter cardiac conduction; life-threatening arrhythmias have occurred with therapeutic doses of antipsychotics. Use caution with history of conduction abnormalities. Relative to other neuroleptics, risperidone has a low risk of arrhythmias (APA [Lehman 2004]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anticholinergic effects: May cause anticholinergic effects (confusion, agitation, constipation, xerostomia, blurred vision, urinary retention); use with caution in patients with decreased gastrointestinal motility, urinary retention, BPH, xerostomia, or visual problems. Relative to other neuroleptics, risperidone has a low potency of cholinergic blockade (Richelson 1999).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Antiemetic effects: May mask toxicity of other drugs or conditions (eg, intestinal obstruction, Reyes syndrome, brain tumor) due to antiemetic effects.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Blood dyscrasias: Leukopenia, neutropenia, and agranulocytosis (sometimes fatal) have been reported in clinical trials and postmarketing reports with antipsychotic use; presence of risk factors (eg, pre-existing low WBC or history of drug-induced leuko-/neutropenia) should prompt periodic blood count assessment. Discontinue therapy at first signs of blood dyscrasias or if absolute neutrophil count &lt;1,000/mm<sup>3</sup>.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cerebrovascular effects: An increased incidence of cerebrovascular effects (eg, transient ischemic attack, stroke), including fatalities, has been reported in placebo-controlled trials of risperidone for the unapproved use in elderly patients with dementia-related psychosis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks that require mental alertness (eg, operating machinery, driving). May be low to moderately sedating in comparison with other antipsychotics (Richelson 1999); dose-related effects have been observed.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Dyslipidemia: Has been reported with atypical antipsychotics; risk profile may differ between agents. Discrepant results have been reported in clinical trials, regarding lipid changes associated with risperidone (American Diabetes Association, 2004).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Esophageal dysmotility/aspiration: Antipsychotic use has been associated with esophageal dysmotility and aspiration; use with caution in patients at risk of pneumonia (eg, Alzheimer disease).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Extrapyramidal symptoms: May cause extrapyramidal symptoms (EPS), including pseudoparkinsonism, acute dystonic reactions, akathisia, and tardive dyskinesia (risk of these reactions is generally much lower relative to typical/conventional antipsychotics; frequencies reported are similar to placebo). Risk of dystonia (and possibly other EPS) may be greater with increased doses, use of conventional antipsychotics, males, and younger patients. Factors associated with greater vulnerability to tardive dyskinesia include older in age, female gender combined with postmenopausal status, Parkinson disease, pseudoparkinsonism symptoms, affective disorders (particularly major depressive disorder), concurrent medical diseases such as diabetes, previous brain damage, alcoholism, poor treatment response, and use of high doses of antipsychotics (APA [Lehman 2004]; Soares-Weiser 2007). Consider therapy discontinuation with signs/symptoms of tardive dyskinesia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Falls: May increase the risk for falls due to somnolence, orthostatic hypotension, and motor or sensory instability. Complete fall risk assessments at baseline and periodically during treatment in patients with diseases or on medications that may also increase fall risk.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hyperglycemia: Atypical antipsychotics have been associated with development of hyperglycemia; in some cases, may be extreme and associated with ketoacidosis, hyperosmolar coma, or death. Use with caution in patients with diabetes or other disorders of glucose regulation; monitor for worsening of glucose control.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hyperprolactinemia: Risperidone is associated with greater increases in prolactin levels as compared to other antipsychotic agents; clinical significance of hyperprolactinemia in patients with breast cancer or other prolactin-dependent tumors is unknown. Risk factors for hyperprolactinemia in patients taking risperidone include female gender, younger age at onset of illness, and higher scores on the Positive and Negative Symptom Scale (PANSS). Additionally, higher doses are associated with greater elevations in prolactin concentrations (Bo 2016).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Hypersensitivity reactions including anaphylactic reactions and angioedema have been reported.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Intraoperative floppy iris syndrome: Few case reports describe intraoperative floppy iris syndrome (IFIS) in patients receiving risperidone and undergoing cataract surgery (Ford 2011). Prior to cataract surgery, evaluate for prior or current risperidone use. The benefits or risks of interrupting risperidone prior to surgery have not been established; clinicians are advised to proceed with surgery cautiously.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neuroleptic malignant syndrome (NMS): Use may be associated with neuroleptic malignant syndrome (NMS); monitor for mental status changes, fever, muscle rigidity, and/or autonomic instability.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Orthostatic hypotension: May cause orthostatic hypotension; use with caution in patients at risk of this effect (eg, concurrent medication use which may predispose to hypotension/bradycardia or presence of hypovolemia) or in those who would not tolerate transient hypotensive episodes. Use caution with history of cerebrovascular or cardiovascular disease (MI, heart failure, or ischemic disease).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Priapism: Rare cases of priapism have been reported.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Suicidal ideation: The possibility of a suicide attempt is inherent in psychotic illness or bipolar disorder; use with caution in high-risk patients during initiation of therapy. Prescriptions should be written for the smallest quantity consistent with good patient care.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Temperature regulation: Impaired core body temperature regulation may occur; caution with strenuous exercise, heat exposure, dehydration, and concomitant medication possessing anticholinergic effects (Kwok 2005, Martinez 2002).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Weight gain: Significant weight gain has been observed with antipsychotic therapy; incidence varies with product. Monitor waist circumference and BMI.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Use with caution in patients with severe cardiac disease, hemodynamic instability, prior myocardial infarction or ischemic heart disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Dementia: <b>[US Boxed Warning]: Elderly patients with dementia-related psychosis treated with antipsychotics are at an increased risk of death compared to placebo.</b> Most deaths appeared to be either cardiovascular (eg, heart failure, sudden death) or infectious (eg, pneumonia) in nature. Use with caution in patients with Lewy body dementia or Parkinson disease dementia due to greater risk of adverse effects, increased sensitivity to extrapyramidal effects, and association with irreversible cognitive decompensation or death. (APA [Reus 2016]). Risperidone is not approved for the treatment of dementia-releated psychosis. Careful assessment of risk factors for stroke or existing cardiovascular morbidities is required prior to initiation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with hepatic disease or impairment; dosage reduction is recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Parkinson disease: Use with caution in patients with Parkinson disease; antipsychotics may aggravate the motor disturbances of Parkinson disease (APA [Lehman 2004]; APA [Reus 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal disease; dosage reduction is recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Seizures: Use with caution in patients at risk of seizures, including those with a history of seizures, head trauma, brain damage, alcoholism, or concurrent therapy with medications which may lower seizure threshold.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Benzyl alcohol and derivatives: Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP [&quot;Inactive&quot; 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates. See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Dispersible tablet: Inform patients with phenylketonuria that dispersible tablets contain phenylalanine.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Injectable suspension: Vehicle used (polylactide-co-glycolide microspheres) has rarely been associated with retinal artery occlusion in patients with abnormal arteriovenous anastomosis (eg, patent foramen ovale). Not for IV use; administer only as an intramuscular injection.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>\n          <b>Other warnings/precautions</b>:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Discontinuation of therapy<b>: </b>When discontinuing antipsychotic therapy, the American Psychiatric Association (APA), Canadian Psychiatric Association (CPA), and World Federation of Societies of Biological Psychiatry (WFSBP) guidelines recommend gradually tapering antipsychotics to avoid physical withdrawal symptoms, including anorexia, anxiety, diaphoresis, diarrhea, dizziness, dyskinesia, headache, myalgia, nausea, paresthesia, restlessness, tremulousness, and vomiting (APA [Lehman 2004]; CPA [Addington 2005]; Lambert 2007; WFSBP [Hasan 2012]). The risk of withdrawal symptoms is highest following abrupt discontinuation of highly anti-cholinergic or dopaminergic antipsychotics (Cerovecki 2013). Additional factors such as duration of antipsychotic exposure, the indication for use, medication half-life, and risk for relapse should be considered. In schizophrenia, there is no reliable indicator to differentiate the minority who will not from the majority who will relapse with drug discontinuation. However, studies in which the medication of well-stabilized patients were discontinued indicate that 75% of patients relapse within 6 to 24 months. Indefinite maintenance antipsychotic medication is generally recommended, and especially for patients who have had multiple prior episodes or 2 episodes within 5 years (APA [Lehman 2004]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25882045\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Use with caution in children and adolescents; adverse effects due to elevated prolactin levels have been observed; long-term effects on growth or sexual maturation have not been evaluated.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Risperidone may cause a higher than normal weight gain in children and adolescents; monitor growth (including weight, height, BMI, and waist circumference) in pediatric patients receiving risperidone; compare weight gain to standard growth curves. Risperidone may cause increases in metabolic indices (eg, serum cholesterol, triglycerides). <b>Note:</b> A prospective, nonrandomized cohort study followed 338 antipsychotic naive pediatric patients (age 4 to 19 years) for a median 10.8 weeks (range 10.5 to 11.2 weeks) and reported the following significant mean increases in weight in kg (and % change from baseline): Olanzapine: 8.5 kg (15.2%), quetiapine: 6.1 kg (10.4%), risperidone: 5.3 kg (10.4%), and aripiprazole: 4.4 kg (8.1%) compared to the control cohort: 0.2 kg (0.65%). Increases in metabolic indices (eg, serum cholesterol, triglycerides) were also reported; a significant increase in serum triglycerides of 9.7 mg/mL was observed for patients receiving risperidone. Biannual monitoring of cardiometabolic indices after the first 3 months of therapy is suggested (Correll 2009).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Hyperglycemia has been reported with risperidone; in analysis of pediatric trials (patients 5 to 17 years, diagnosis including schizophrenia, autistic disorder, and bipolar disorder, risperidone therapy was associated with a greater mean change in fasting glucose than placebo-treated patients (2.6 mg/dL vs -1.3 mg/dL; exposure: 3 to 6 weeks); with longer exposure (24 weeks), a mean fasting glucose change of +5.2 mg/dL was reported. However, with longer exposure (mean: 17.2 months), an increased risk for the development of type 2 diabetes mellitus (DM) was observed in pediatric patients 10 to 18 years receiving second-generation antipsychotics (SGA); for patients initiated on SGA: 0.4% incidence with mean exposure at time type 2 DM diagnosed: 13.5 months; for SGA noniniators (patients receiving another agent prior to SGA initiation): 0.2% incidence with mean exposure at time of type 2 DM diagnosed: 14.6 months. Amongst specific SGAs, the risk was highest for aripiprazole (p=0.001) followed by ziprasidone (p=0.06) compared to risperidone as the reference group but not quetiapine or olanzapine (Rubin 2015).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Children may experience a higher frequency of certain adverse effects than adults, particularly fatigue (18% to 42% vs &le;3%), somnolence (12% to 67% vs &le;14%), fever (20% vs 2%), constipation (21% vs 9%), increased salivation (22% vs 3%), abdominal pain (18% vs 4%), and dry mouth (13% vs 4%).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Long-term usefulness of risperidone should be periodically re-evaluated in patients receiving the drug for extended periods of time.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218697\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP2D6 (major), CYP3A4 (minor), P-glycoprotein/ABCB1; <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218625\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12770&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Abiraterone Acetate: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Management: Avoid concurrent use of abiraterone with CYP2D6 substrates that have a narrow therapeutic index whenever possible.  When concurrent use is not avoidable, monitor patients closely for signs/symptoms of toxicity.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">AbobotulinumtoxinA: Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Acetylcholinesterase Inhibitors: May diminish the therapeutic effect of Anticholinergic Agents. Anticholinergic Agents may diminish the therapeutic effect of Acetylcholinesterase Inhibitors.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Acetylcholinesterase Inhibitors (Central): May enhance the neurotoxic (central) effect of Antipsychotic Agents. Severe extrapyramidal symptoms have occurred in some patients.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aclidinium: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amifampridine: May diminish the anticholinergic effect of Anticholinergic Agents. Anticholinergic Agents may diminish the therapeutic effect of Amifampridine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amisulpride: Antipsychotic Agents may enhance the adverse/toxic effect of Amisulpride. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amphetamines: Antipsychotic Agents may diminish the stimulatory effect of Amphetamines. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anticholinergic Agents: May enhance the adverse/toxic effect of other Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antidiabetic Agents: Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anti-Parkinson Agents (Dopamine Agonist): Antipsychotic Agents (Second Generation [Atypical]) may diminish the therapeutic effect of Anti-Parkinson Agents (Dopamine Agonist).  Management: Consider using an alternative antipsychotic agent when possible in patients with Parkinson disease.  If an atypical antipsychotic is necessary, consider using clozapine or quetiapine, which may convey the lowest interaction risk.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Asunaprevir: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blood Pressure Lowering Agents: May enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromopride: May enhance the adverse/toxic effect of Antipsychotic Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine patches (Butrans brand) at 5 mcg/hr in adults when used with other CNS depressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BuPROPion: May enhance the neuroexcitatory and/or seizure-potentiating effect of Agents With Seizure Threshold Lowering Potential.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabis: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CarBAMazepine: May decrease the serum concentration of RisperiDONE. Management: Consider increasing the dose of risperidone (to no more than double the original dose) if carbamazepine is initiated/dose increased. Monitor for reduced therapeutic effects of risperidone.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloral Betaine: May enhance the adverse/toxic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cimetropium: Anticholinergic Agents may enhance the anticholinergic effect of Cimetropium. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cobicistat: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2D6 Inhibitors (Moderate): May decrease the metabolism of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2D6 Inhibitors (Strong): May decrease the metabolism of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Darunavir: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Doxylamine: May enhance the CNS depressant effect of CNS Depressants. Management: The manufacturer of Diclegis (doxylamine/pyridoxine), intended for use in pregnancy, specifically states that use with other CNS depressants is  not recommended.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dronabinol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eluxadoline: Anticholinergic Agents may enhance the constipating effect of Eluxadoline. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal Agents (Prokinetic): Anticholinergic Agents may diminish the therapeutic effect of Gastrointestinal Agents (Prokinetic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Glucagon: Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Glycopyrrolate (Oral Inhalation): Anticholinergic Agents may enhance the anticholinergic effect of Glycopyrrolate (Oral Inhalation). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Guanethidine: Antipsychotic Agents may diminish the therapeutic effect of Guanethidine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HYDROcodone: CNS Depressants may enhance the CNS depressant effect of HYDROcodone.  Management: Avoid concomitant use of hydrocodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hydroxychloroquine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Imatinib: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iohexol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iohexol. Specifically, the risk for seizures may be increased.  Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iohexol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic anticonvulsants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iomeprol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iomeprol. Specifically, the risk for seizures may be increased.  Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iomeprol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic anticonvulsants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iopamidol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iopamidol. Specifically, the risk for seizures may be increased.  Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iopamidol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic anticonvulsants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Itopride: Anticholinergic Agents may diminish the therapeutic effect of Itopride. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Kava Kava: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Levosulpiride: Anticholinergic Agents may diminish the therapeutic effect of Levosulpiride. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lithium: May enhance the neurotoxic effect of Antipsychotic Agents. Lithium may decrease the serum concentration of Antipsychotic Agents. Specifically noted with chlorpromazine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Loop Diuretics: May enhance the adverse/toxic effect of RisperiDONE. Management: Consider alternative diuretic therapy (e.g., thiazides) to more potent diuretics (e.g., furosemide) in elderly patients receiving risperidone. Patients who require use of more potent diuretic therapy should be closely monitored and adequately hydrated.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lumacaftor: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. Lumacaftor may increase the serum concentration of P-glycoprotein/ABCB1 Substrates.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Macimorelin: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mequitazine: Antipsychotic Agents may enhance the arrhythmogenic effect of Mequitazine.  Management: Consider alternatives to one of these agents when possible.  While this combination is not specifically contraindicated, mequitazine labeling describes this combination as discouraged.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methylphenidate: Antipsychotic Agents may enhance the adverse/toxic effect of Methylphenidate. Methylphenidate may enhance the adverse/toxic effect of Antipsychotic Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metoclopramide: May enhance the adverse/toxic effect of Antipsychotic Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MetyroSINE: May enhance the adverse/toxic effect of Antipsychotic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mianserin: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Minocycline: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mirabegron: Anticholinergic Agents may enhance the adverse/toxic effect of Mirabegron. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nabilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nitroglycerin: Anticholinergic Agents may decrease the absorption of Nitroglycerin. Specifically, anticholinergic agents may decrease the dissolution of sublingual nitroglycerin tablets, possibly impairing or slowing nitroglycerin absorption. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OnabotulinumtoxinA: Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Opioid Analgesics: CNS Depressants may enhance the CNS depressant effect of Opioid Analgesics.  Management: Avoid concomitant use of opioid analgesics and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oxatomide: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oxomemazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE.  Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Paliperidone: RisperiDONE may enhance the adverse/toxic effect of Paliperidone.  Management: Additive paliperidone exposure is expected with this combination.  Consider using an alternative combination when possible.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Panobinostat: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Management: Avoid concurrent use of sensitive CYP2D6 substrates when possible, particularly those substrates with a narrow therapeutic index.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Peginterferon Alfa-2b may increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Perhexiline: CYP2D6 Substrates (High risk with Inhibitors) may increase the serum concentration of Perhexiline. Perhexiline may increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Piribedil: Antipsychotic Agents may diminish the therapeutic effect of Piribedil. Piribedil may diminish the therapeutic effect of Antipsychotic Agents.  Management: Use of piribedil with antiemetic neuroleptics is contraindicated, and use with antipsychotic neuroleptics, except for clozapine, is not recommended.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Potassium Chloride: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Chloride.  Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium chloride.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Potassium Citrate: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Citrate. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pramlintide: May enhance the anticholinergic effect of Anticholinergic Agents. These effects are specific to the GI tract.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Probucol: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promazine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Highest Risk): QTc-Prolonging Agents (Moderate Risk) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying): May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Moderate Risk): May enhance the QTc-prolonging effect of other QTc-Prolonging Agents (Moderate Risk). Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinagolide: Antipsychotic Agents may diminish the therapeutic effect of Quinagolide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ramosetron: Anticholinergic Agents may enhance the constipating effect of Ramosetron. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ranolazine: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">RimabotulinumtoxinB: Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Secretin: Anticholinergic Agents may diminish the therapeutic effect of Secretin.  Management: Avoid concomitant use of anticholinergic agents and secretin. Discontinue anticholinergic agents at least 5 half-lives prior to administration of secretin.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Selective Serotonin Reuptake Inhibitors: May decrease the metabolism of RisperiDONE.<b> Exceptions: </b>FluvoxaMINE.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Serotonin Modulators: May enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.<b> Exceptions: </b>Nicergoline.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sulpiride: Antipsychotic Agents may enhance the adverse/toxic effect of Sulpiride. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant.  Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary.  Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tapentadol: May enhance the CNS depressant effect of CNS Depressants. Management: Avoid concomitant use of tapentadol and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetrahydrocannabinol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thiazide and Thiazide-Like Diuretics: Anticholinergic Agents may increase the serum concentration of Thiazide and Thiazide-Like Diuretics. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tiotropium: Anticholinergic Agents may enhance the anticholinergic effect of Tiotropium. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Topiramate: Anticholinergic Agents may enhance the adverse/toxic effect of Topiramate. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trimeprazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Umeclidinium: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Valproate Products: May enhance the adverse/toxic effect of RisperiDONE. Generalized edema has developed.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Verapamil: May increase the serum concentration of RisperiDONE.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vinflunine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Xipamide: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for  men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218655\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Oral solution is not compatible with beverages containing tannin or pectinate (cola or tea). Management: Administer oral solution with water, coffee, orange juice, or low-fat milk.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218627\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2888768\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were observed in animal reproduction studies. In human studies, risperidone and its metabolite cross the placenta (Newport 2007). Agenesis of the corpus callosum has been noted in one case report of an infant exposed to risperidone in utero; relationship to risperidone exposure is not known. Antipsychotic use during the third trimester of pregnancy has a risk for extrapyramidal symptoms (EPS) and/or withdrawal symptoms in newborns following delivery. Symptoms in the newborn may include agitation, feeding disorder, hypertonia, hypotonia, respiratory distress, somnolence, and tremor. These effects may be self-limiting and allow recovery within hours or days with no specific treatment, or they may be severe requiring prolonged hospitalization.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">When using Risperdal Consta, patients should notify health care provider if they become or intend to become pregnant during therapy or within 12 weeks of last injection.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The ACOG recommends that therapy during pregnancy be individualized; treatment with psychiatric medications during pregnancy should incorporate the clinical expertise of the mental health clinician, obstetrician, primary health care provider, and pediatrician. Safety data related to atypical antipsychotics during pregnancy is limited. As a result, routine use is not recommended. However, if a woman is inadvertently exposed to an atypical antipsychotic while pregnant, continuing therapy may be preferable to switching to an agent that the fetus has not yet been exposed to; consider risk:benefit (ACOG 2008). If treatment is needed in a woman planning a pregnancy or if treatment is initiated during pregnancy, use of an agent other than risperidol is preferred (Larsen 2015).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Risperidone may cause hyperprolactinemia, which may decrease reproductive function in both males and females.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Healthcare providers are encouraged to enroll women 18 to 45 years of age exposed to risperidone during pregnancy in the Atypical Antipsychotics Pregnancy Registry (1-866-961-2388 or http://www.womensmentalhealth.org/pregnancyregistry).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1055299\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Blood pressure (including orthostatic) and heart rate, particularly during dosage titration; mental status, abnormal involuntary movement scale (AIMS), and extrapyramidal symptoms; growth, BMI, waist circumference, and weight (in adults, weight should be assessed prior to treatment and at 4 weeks, 8 weeks, 12 weeks, and then at quarterly intervals; consider titrating to a different antipsychotic agent for a weight gain &ge;5% of the initial weight); CBC with differential; liver enzymes in children (especially obese children or those who are rapidly gaining weight while receiving therapy); lipid profile; fasting blood glucose/Hgb A<sub>1c</sub> (prior to treatment, at 3 months, then annually); prolactin serum concentrations</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218620\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Risperidone is a benzisoxazole atypical antipsychotic with high 5-HT<sub>2</sub>- dopamine-D<sub>2</sub> receptor antagonist activity. Alpha<sub>1</sub>, alpha<sub>2</sub> adrenergic, and histaminergic receptors are also antagonized with high affinity. Risperidone has low to moderate affinity for 5-HT<sub>1C</sub>, 5-HT<sub>1D</sub>, and 5-HT<sub>1A</sub> receptors, weak affinity for D<sub>1</sub> and no affinity for muscarinics or beta<sub>1</sub> and beta<sub>2</sub> receptors.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218637\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note: </b>Following oral administration, the pharmacokinetics of risperidone and 9-hydroxyrisperidone in children were found to be similar to values in adults (after adjusting for differences in body weight).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: Rapid and well absorbed; food does not affect rate or extent</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Injection: &lt;1% absorbed initially; main release occurs at ~3 weeks and is maintained from 4 to 6 weeks; release ends by 7 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub>: 1 to 2 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding, plasma: Risperidone 90%; 9-hydroxyrisperidone: 77%; <b>Note: </b>Risperidone free fraction may be increased by ~35% in patients with hepatic impairment due to decreased concentrations of albumin and alpha-1 acid glycoprotein</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Extensively hepatic via CYP2D6 to 9-hydroxyrisperidone (similar pharmacological activity as risperidone); <i>N</i>-dealkylation is a second minor pathway; <b>Note:</b> 9-hydroxyrisperidone is the predominant circulating form and is approximately equal to risperidone in receptor binding activity; clinical effects are from combined concentrations of risperidone and 9-hydroxyrisperidone; clinically important differences between CYP2D6 poor and extensive metabolizers are not expected (pharmacokinetics of the sum of risperidone and 9-hydroxyrisperidone were similar in poor and extensive metabolizers)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: 70%; Tablet (relative to solution): 94%; orally-disintegrating tablets and oral solution are bioequivalent to tablets</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Injection: Deltoid IM injection is bioequivalent to gluteal IM injection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Active moiety (risperidone and its active metabolite 9-hydroxyrisperidone):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: 20 hours (mean); prolonged in elderly patients</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Extensive metabolizers: Risperidone: 3 hours; 9-hydroxyrisperidone: 21 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Poor metabolizers: Risperidone: 20 hours; 9-hydroxyrisperidone: 30 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Injection: 3 to 6 days; related to microsphere erosion and subsequent absorption of risperidone</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, plasma: Oral: Risperidone: Within 1 hour; 9-hydroxyrisperidone: Extensive metabolizers: 3 hours; Poor metabolizers: 17 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (70%); feces (14%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218641\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (RisperDAL Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg/mL (30 mL): $430.81</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (RisperiDONE Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg/mL (30 mL): $152.56</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension (reconstituted)</b> (RisperDAL Consta Intramuscular)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">12.5 mg (1): $272.10</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg (1): $544.15</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">37.5 mg (1): $816.26</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (1): $1,088.38</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, orally-disintegrating</b> (RisperDAL M-TAB Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.5 mg (28): $353.68</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg (28): $413.24</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">3 mg (28): $847.69</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 mg (28): $1,138.61</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, orally-disintegrating</b> (RisperiDONE M-TAB Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.5 mg (28): $131.86</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg (28): $154.07</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 mg (28): $250.49</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, orally-disintegrating</b> (RisperiDONE Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.25 mg (1): $4.48</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.5 mg (30): $147.49</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg (28): $154.07</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 mg (28): $250.49</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">3 mg (28): $316.12</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 mg (28): $424.45</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (RisperDAL Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.25 mg (100): $1,101.60</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.5 mg (100): $1,208.88</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg (100): $1,285.08</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 mg (100): $2,147.88</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">3 mg (100): $2,522.88</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 mg (60): $2,033.21</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (RisperiDONE Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.25 mg (60): $234.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.5 mg (60): $256.31</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg (60): $273.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 mg (60): $456.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">3 mg (60): $535.93</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 mg (60): $720.00</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218644\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Aleptolan (LV);</li>\n      <li>Anxilet (TW);</li>\n      <li>Arketin (ES);</li>\n      <li>Aspidon (PH);</li>\n      <li>Calmapride (ES);</li>\n      <li>Diaforin (ES);</li>\n      <li>Dyperidone (PH);</li>\n      <li>Eperon (SG);</li>\n      <li>Eridon (UA);</li>\n      <li>Goval (EC);</li>\n      <li>Ispidon (PE);</li>\n      <li>Luvenil (PY);</li>\n      <li>Mirabril (PY);</li>\n      <li>Neorisp (BG);</li>\n      <li>Neripros (ID);</li>\n      <li>Neuris (TH);</li>\n      <li>Nodiril (MT);</li>\n      <li>Noprenia (ID);</li>\n      <li>Noprenia OS (ID);</li>\n      <li>Ozidal (AU);</li>\n      <li>Perdamel (IE, MT);</li>\n      <li>Persidal-2 (ID);</li>\n      <li>Prospera (HR);</li>\n      <li>Raxidone (QA);</li>\n      <li>Renuvie (PH);</li>\n      <li>Resdone (AU);</li>\n      <li>Respal (LB, QA);</li>\n      <li>Resperiteg (NI);</li>\n      <li>Revoc (LK);</li>\n      <li>Riatul (EC);</li>\n      <li>Ridal (NZ, SG);</li>\n      <li>Ridkline (MY);</li>\n      <li>Rileptid (HK, RO, VN);</li>\n      <li>Riper (TW);</li>\n      <li>Riperidon (KR);</li>\n      <li>Riscord (LK);</li>\n      <li>Risdin (PH);</li>\n      <li>Risdon (TW);</li>\n      <li>Risfree (KR);</li>\n      <li>Risnia (HR);</li>\n      <li>Rison (RO);</li>\n      <li>Risoperin (KR);</li>\n      <li>Rispa (AU);</li>\n      <li>Rispaxol (LV);</li>\n      <li>Rispefar (SG);</li>\n      <li>Risperdal (AE, AR, AT, AU, BB, BD, BE, BF, BH, BJ, BO, BR, CH, CI, CL, CN, CO, CY, CZ, DE, DK, EC, EE, EG, ES, ET, FI, FR, GB, GH, GM, GN, GR, HK, ID, IE, IL, IQ, IR, IS, IT, JO, JP, KE, KR, KW, LB, LK, LR, LY, MA, ML, MR, MT, MU, MW, MX, MY, NE, NG, NO, NZ, OM, PE, PH, PK, PT, QA, SA, SC, SD, SE, SG, SI, SK, SL, SN, SY, TH, TN, TR, TW, TZ, UG, UY, VE, VN, YE, ZA, ZM, ZW);</li>\n      <li>Risperdal Const (BM, BS, BZ, GY, JM, NL, PR, SR, TT);</li>\n      <li>Risperdal Consta (AE, AU, BB, BH, CH, CN, CY, DE, EC, ES, GB, HK, ID, IE, IL, IS, JO, KR, KW, LB, MT, MY, NO, NZ, PE, PH, QA, SA, SE, SG, SI, SK, TH, TW);</li>\n      <li>Risperdal OD (JP);</li>\n      <li>Risperdal Quicklet (AU, BM, BS, BZ, DE, GB, GY, HK, IE, JM, NL, NZ, PH, PR, SG, SI, SR, TH, TT);</li>\n      <li>Risperdalconsta LP (FR);</li>\n      <li>Risperidex (IL);</li>\n      <li>Risperigamma (HK);</li>\n      <li>Risperiteg (CR, DO, GT, HN, PA, SV);</li>\n      <li>Risperon (NZ, VN);</li>\n      <li>Rispeva (IE);</li>\n      <li>Rispid (IN);</li>\n      <li>Rispolept (LV, RU);</li>\n      <li>Rispolet (EE);</li>\n      <li>Rispond (IL, LK, PH);</li>\n      <li>Rispone (IE);</li>\n      <li>Rispons (HK);</li>\n      <li>Risset (HR);</li>\n      <li>Rixadone (AU);</li>\n      <li>Ryspolept (UA);</li>\n      <li>Rysset (UA);</li>\n      <li>Saxid (QA);</li>\n      <li>Sequinan (AR);</li>\n      <li>Spiron (EC);</li>\n      <li>Steviso (PH);</li>\n      <li>Torendo (BG, UA);</li>\n      <li>Xenoma (RO);</li>\n      <li>Zofredal (ID);</li>\n      <li>Zyresp (VN);</li>\n      <li>&Ntilde;orispez (MX)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Aman MG, De Smedt G, Derivan A, et al, &quot;Double-Blind, Placebo-Controlled Study of Risperidone for the Treatment of Disruptive Behaviors in Children With Subaverage Intelligence,&quot; <i>Am J Psychiatry</i>, 2002, 159(8):1337-46.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/risperidone-pediatric-drug-information/abstract-text/12153826/pubmed\" target=\"_blank\" id=\"12153826\">12153826</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics Committee on Drugs. &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/risperidone-pediatric-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists, ACOG Practice Bulletin: Clinical Management Guidelines for Obstetricians-Gynecologists No. 92 April 2008 (Replaces Practice Bulletin Number 87, November 2007), &ldquo;Use of Psychiatric Medications During Pregnancy and Lactation,&rdquo; <i>Obstet Gynecol</i>, 2008, 111(4):1001-20.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/risperidone-pediatric-drug-information/abstract-text/18378767/pubmed\" target=\"_blank\" id=\"18378767\">18378767</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, and North American Association for the Study of Obesity, &quot;Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes,&quot; <i>Diabetes Care</i>, 2004, 27(2):596-601.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/risperidone-pediatric-drug-information/abstract-text/14747245/pubmed\" target=\"_blank\" id=\"14747245\">14747245</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bruggeman R, van der Linden C, Buitelaar JK, et al, &quot;Risperidone Versus Pimozide in Tourette's Disorder: A Comparative Double-Blind Parallel-Group Study,&quot; <i>J Clin Psychiatry</i>, 2001, 62(1):50-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/risperidone-pediatric-drug-information/abstract-text/11235929/pubmed\" target=\"_blank\" id=\"11235929\">11235929</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"16529334\"></a>Canadian Psychiatric Association (CPA). Clinical practice guidelines. Treatment of schizophrenia. <i>Can J Psychiatry</i>. 2005;50(13 Suppl 1):7S-57S.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/risperidone-pediatric-drug-information/abstract-text/16529334/pubmed\" target=\"_blank\" id=\"16529334\">16529334</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol - United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/risperidone-pediatric-drug-information/abstract-text/6810084 /pubmed\" target=\"_blank\" id=\"6810084 \">6810084 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23821039\"></a>Cerovecki A, Musil R, Klimke A, et al. Withdrawal symptoms and rebound syndromes associated with switching and discontinuing atypical antipsychotics: theoretical background and practical recommendations. <i>CNS Drugs</i>. 2013;27(7):545-572.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/risperidone-pediatric-drug-information/abstract-text/23821039/pubmed\" target=\"_blank\" id=\"23821039\">23821039</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Coppola D, Russo LJ, Kwarta RF Jr, et al, &quot;Evaluating the Postmarketing Experience of Risperidone Use During Pregnancy: Pregnancy and Neonatal Outcomes,&quot; <i>Drug Saf,</i> 2007, 30(3):247-64.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/risperidone-pediatric-drug-information/abstract-text/17343431/pubmed\" target=\"_blank\" id=\"17343431\">17343431</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Correll CU, Manu P, Olshanskiy V, et al, &quot;Cardiometabolic Risk of Second-Generation Antipsychotic Medications During First-Time Use in Children and Adolescents,&quot; <i>JAMA</i>, 2009, 302(16):1765-73.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/risperidone-pediatric-drug-information/abstract-text/19861668/pubmed\" target=\"_blank\" id=\"19861668\">19861668</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dion Y, Annable L, Sandor P, et al, &quot;Risperidone in the Treatment of Tourette Syndrome: A Double-Blind, Placebo-Controlled Trial,&quot; <i>J Clin Psychopharmacol</i>, 2002, 22(1):31-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/risperidone-pediatric-drug-information/abstract-text/11799340/pubmed\" target=\"_blank\" id=\"11799340\">11799340</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Donfrancesco R, Calderoni D, and Vitiello B, &quot;Open-Label Amantadine in Children With Attention-Deficit/Hyperactivity Disorder,&quot; <i>J Child Adolesc Psychopharmacol</i>, 2007, 17(5):657-64.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/risperidone-pediatric-drug-information/abstract-text/17979585/pubmed\" target=\"_blank\" id=\"17979585\">17979585</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Findling RL, Aman MG, Eerdekens M, et al, &quot;Long-Term, Open-Label Study of Risperidone in Children With Severe Disruptive Behaviors and Below-Average IQ,&quot; <i>Am J Psychiatry</i>, 2004, 161(4):677-84.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/risperidone-pediatric-drug-information/abstract-text/15056514/pubmed\" target=\"_blank\" id=\"15056514\">15056514</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fisman S and Steele M, &quot;Use of Risperidone in Pervasive Developmental Disorders: A Case Series,&quot; <i>J Child Adolesc Psychopharmacol</i>, 1996, 6(3):177-90.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/risperidone-pediatric-drug-information/abstract-text/9231311 /pubmed\" target=\"_blank\" id=\"9231311 \">9231311 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ford RL, Sallam A, Towler HM. Intraoperative floppy iris syndrome associated with risperidone intake. <i>Eur J Ophthalmol</i>. 2011;21(2):210-211.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fu-I L, Boarati MA, Stravogiannis A, et al, &quot;Use of Risperidone Long-Acting Injection to Support Treatment Adherence and Mood Stabilization in Pediatric Bipolar Patients: A Case Series,&quot; <i>J Clin Psychiatry</i>, 2009, 70(4):604-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/risperidone-pediatric-drug-information/abstract-text/19403102/pubmed\" target=\"_blank\" id=\"19403102\">19403102</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"22834451\"></a>Hasan A, Falkai P, Wobrock T, et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. <i>World J Biol Psychiatry</i>. 2012;13(5):318-378.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/risperidone-pediatric-drug-information/abstract-text/22834451/pubmed\" target=\"_blank\" id=\"22834451\">22834451</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hill RC, McIvor RJ, Wojnar-Horton RE, et al, &quot;Risperidone Distribution and Excretion Into Human Milk: Case Report and Estimated Infant Exposure During Breast-Feeding,&quot; <i>J Clin Psychopharmacol</i>, 2000, 20(2):285-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/risperidone-pediatric-drug-information/abstract-text/10770482/pubmed\" target=\"_blank\" id=\"10770482\">10770482</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ipser J and Stein DJ, &quot;Systematic Review of Pharmacotherapy of Disruptive Behavior Disorders in Children and Adolescents,&quot; <i>Psychopharmacology (Berl)</i>, 2007, 191(1):127-40.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/risperidone-pediatric-drug-information/abstract-text/16983542/pubmed\" target=\"_blank\" id=\"16983542\">16983542</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Karnik NS, Joshi SV, Paterno C, et al, &quot;Subtypes of Pediatric Delirium: A Treatment Algorithm,&quot; <i>Psychosomatics</i>, 2007, 48(3):253-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/risperidone-pediatric-drug-information/abstract-text/17478595/pubmed\" target=\"_blank\" id=\"17478595\">17478595</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kumra S, Herion D, Jacobsen LK, et al, &quot;Case Study: Risperidone-Induced Hepatotoxicity in Pediatric Patients,&quot; <i>J Am Acad Child Adolesc Psychiatry</i>, 1997, 36(5):701-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/risperidone-pediatric-drug-information/abstract-text/9136506 /pubmed\" target=\"_blank\" id=\"9136506 \">9136506 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kutcher S, Aman M, Brooks SJ, et al, &quot;International Consensus Statement on Attention-Deficit/Hyperactivity Disorder (ADHD) and Disruptive Behaviour Disorders (DBDs): Clinical Implications and Treatment Practice Suggestions,&quot; <i>Eur Neuropsychopharmacol</i>, 2004, 14(1):11-28.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/risperidone-pediatric-drug-information/abstract-text/14659983/pubmed\" target=\"_blank\" id=\"14659983\">14659983</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"15000267\"></a>Lehman AF, Lieberman JA, Dixon LB, et al. Practice guideline for the treatment of patients with schizophrenia, second edition. <i>Am J Psychiatry</i>. 2004;161(2 Suppl):1-56.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/risperidone-pediatric-drug-information/abstract-text/15000267/pubmed\" target=\"_blank\" id=\"15000267\">15000267</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lombroso PJ, Scahill L, King RA, et al, &quot;Risperidone Treatment of Children and Adolescents With Chronic Tic Disorders: A Preliminary Report,&quot; <i>J Am Acad Child Adolesc Psychiatry</i>, 1995, 34(9):1147-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/risperidone-pediatric-drug-information/abstract-text/7559308/pubmed\" target=\"_blank\" id=\"7559308\">7559308</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"17195735\"></a>McClellan J, Kowatch R, Findling RL; Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with bipolar disorder. <i>J Am Acad Child Adolesc Psychiatry</i>. 2007;46(1):107-125.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/risperidone-pediatric-drug-information/abstract-text/17195735/pubmed\" target=\"_blank\" id=\"17195735\">17195735</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McDougle CJ, Holmes JP, Bronson MR, et al, &quot;Risperidone Treatment of Children and Adolescents With Pervasive Developmental Disorders: A Prospective Open-Label Study,&quot; <i>J Am Acad Child Adolesc Psychiatry</i>, 1997, 36(5):685-93.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/risperidone-pediatric-drug-information/abstract-text/9136504 /pubmed\" target=\"_blank\" id=\"9136504 \">9136504 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      National Institute for Health and Clinical Excellence (NICE), National Collaborating Centre for Mental Health. Psychosis and schizophrenia in children and young people: recognition and management. 2013. Available at https://www.nice.org.uk/guidance/cg155.26065063</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Newport DJ, Calamaras MR, DeVane CL, et al, &ldquo;Atypical Antipsychotic Administration During Late Pregnancy: Placental Passage and Obstetrical Outcomes,&rdquo; <i>Am J Psychiatry</i>, 2007, 164(8):1214-20.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/risperidone-pediatric-drug-information/abstract-text/17671284/pubmed\" target=\"_blank\" id=\"17671284\">17671284</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pandina GJ, Aman MG, and Findling RL, &quot;Risperidone in the Management of Disruptive Behavior Disorders,&quot; <i>J Child Adolesc Psychopharmacol</i>, 2006, 16(4):379-92.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/risperidone-pediatric-drug-information/abstract-text/16958564/pubmed\" target=\"_blank\" id=\"16958564\">16958564</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"15949658\"></a>Remington G, Chue P, Stip E, Kopala L, Girard T, Christensen B. The crossover approach to switching antipsychotics: what is the evidence? <i>Schizophr Res</i>. 2005;76(2-3):267-272.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/risperidone-pediatric-drug-information/abstract-text/15949658/pubmed\" target=\"_blank\" id=\"15949658\">15949658</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Roessner V, Plessen KJ, Rothenberger A, et al, &quot;European Clinical Guidelines for Tourette Syndrome and Other Tic Disorders. Part II: Pharmacological Treatment,&quot; <i>Eur Child Adolesc Psychiatry</i>, 2011, 20(4):173-96.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rubin DM, Kreider AR, Matone M, et al. Risk for incident diabetes mellitus following initiation of second-generation antipsychotics among Medicaid-enrolled youths. <i>JAMA Pediatr</i>. 2015;169(4):e150285.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/risperidone-pediatric-drug-information/abstract-text/25844991/pubmed\" target=\"_blank\" id=\"25844991\">25844991</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sandor P and Stephens RJ, &quot;Risperidone Treatment of Aggressive Behavior in Children With Tourette Syndrome,&quot; <i>J Clin Psychopharmacol</i>, 2000, 20(6):710-2.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/risperidone-pediatric-drug-information/abstract-text/11106151/pubmed\" target=\"_blank\" id=\"11106151\">11106151</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Scahill L, Leckman JF, Schultz RT, et al, &quot;A Placebo-Controlled Trial of Risperidone in Tourette Syndrome,&quot; <i>Neurology</i>, 2003, 60(7):1130-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/risperidone-pediatric-drug-information/abstract-text/12682319/pubmed\" target=\"_blank\" id=\"12682319\">12682319</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schieveld JN, Leroy PL, van Os J, et al, &quot;Pediatric Delirium in Critical Illness: Phenomenology, Clinical Correlates and Treatment Response in 40 Cases in the Pediatric Intensive Care Unit,&quot; <i>Intensive Care Med</i>, 2007, 33(6):1033-40.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/risperidone-pediatric-drug-information/abstract-text/17457571/pubmed\" target=\"_blank\" id=\"17457571\">17457571</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shea S, Turgay A, Carroll A, et al, &quot;Risperidone in the Treatment of Disruptive Behavioral Symptoms in Children With Autistic and Other Pervasive Developmental Disorders,&quot; <i>Pediatrics</i>, 2004, 114(5):e634-41.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/risperidone-pediatric-drug-information/abstract-text/15492353/pubmed\" target=\"_blank\" id=\"15492353\">15492353</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Silver GH, Kearney JA, Kutko MC, et al, &quot;Infant Delirium in Pediatric Critical Care Settings,&quot; <i>Am J Psychiatry</i>, 2010, 167(10):1172-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/risperidone-pediatric-drug-information/abstract-text/20889664/pubmed\" target=\"_blank\" id=\"20889664\">20889664</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Singer HS, &quot;Treatment of Tics and Tourette Syndrome,&quot; <i>Curr Treat Options Neurol</i>, 2010, 12(6):539-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/risperidone-pediatric-drug-information/abstract-text/20848326/pubmed\" target=\"_blank\" id=\"20848326\">20848326</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Smith HA, Fuchs DC, Pandharipande PP, et al, &quot;Delirium: An Emerging Frontier in the Management of Critically Ill Children,&quot; <i>Crit Care Clin</i>, 2009, 25(3):593-614.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/risperidone-pediatric-drug-information/abstract-text/19576533/pubmed\" target=\"_blank\" id=\"19576533\">19576533</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12770 Version 263.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Special Alerts\" href=\"#F50629650\" class=\"outlineLink\">Special Alerts</a></li><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5709402\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F218658\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F218659\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1055300\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1055292\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F218631\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F218617\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1055303\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49133431\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F218653\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1055302\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F218713\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F218711\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F218638\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F218621\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F25882045\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F218697\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F218625\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F218655\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F218627\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F2888768\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1055299\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F218620\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F218637\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F218641\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F218644\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12770|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=risperidone-drug-information\" class=\"drug drug_general\">Risperidone: Drug information</a></li><li><a href=\"topic.htm?path=risperidone-patient-drug-information\" class=\"drug drug_patient\">Risperidone: Patient drug information</a></li></ul></div></div>","javascript":null}